3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Neoplasms
2
Meningioma
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
29
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Gemcitabine
13
apatinib
12
Paclitaxel
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
8
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
vistusertib
×
Clear all
NCT03106155
2018-09-20
[SUKSES-D]
Samsung Medical Center
Phase 2
Terminated
4 enrolled